{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,15]],"date-time":"2026-09-15T21:21:39Z","timestamp":1789507299268,"version":"build-2803163510"},"reference-count":41,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,4,10]],"date-time":"2026-04-10T00:00:00Z","timestamp":1775779200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Pharmacol."],"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Emapalumab, an interferon-\u03b3 (interferon-gamma)\u2013blocking monoclonal antibody, has emerged as a targeted therapy for refractory hemophagocytic lymphohistiocytosis (HLH). This scoping review summarizes real-world evidence of its clinical use across HLH subtypes.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>A comprehensive search of PubMed, Scopus, and Web of Science through September 2025 identified studies reporting emapalumab use outside clinical trials. Case reports, series, and observational studies describing clinical outcomes were included.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Thirty-one publications comprising 86 patients were analyzed. Disease contexts included familial\/genetic HLH (n = 11), rheumatology-associated macrophage activation syndrome (MAS; n = 12), malignancy-associated HLH (n = 25), infection-associated HLH (n = 22), CAR-T\/IEC-HS or cytokine-release-syndrome\u2013related HLH (chimeric antigen receptor T-cell\/immune effector cell\u2013associated hemophagocytic syndrome; n = 11), and other secondary HLH (n = 5). Across all categories, emapalumab achieved rapid suppression of hyperinflammation, typically within 1\u20132\u00a0weeks. Clinical response rates were 100% in familial HLH, 91.7% in rheumatology-associated MAS, 72.7% in infection-associated HLH, 90.9% in CAR-T\/IEC-HS\u2013related HLH, and 80% in other secondary HLH. In contrast, only 6 of 25 patients with malignancy-associated HLH (24%) showed partial or complete responses, reflecting inferior outcomes due to underlying disease progression. Overall survival was highest in familial and infection-associated subgroups. The reported adverse events were generally infrequent and mild in the published cases, but causality cannot be reliably established given the complexity of the underlying disease and concurrent therapies.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Real-world evidence demonstrates that emapalumab induces rapid and durable disease control across diverse HLH subtypes, with a favorable tolerability profile. However, outcomes remain markedly inferior in malignancy-associated HLH, where response rates are limited to approximately 24%, primarily due to the impact of underlying malignancy. Its role as rescue or bridging therapy to hematopoietic stem-cell transplantation (HSCT) is increasingly supported in both pediatric and adult populations.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fphar.2026.1749084","type":"journal-article","created":{"date-parts":[[2026,4,10]],"date-time":"2026-04-10T06:06:41Z","timestamp":1775801201000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":3,"title":["Real-world use of emapalumab in hemophagocytic lymphohistiocytosis: a scoping review of published evidence"],"prefix":"10.3389","volume":"17","author":[{"given":"Abdulrahman F.","family":"Al-Mashdali","sequence":"first","affiliation":[{"name":"Department of Hematology, National Center for Cancer Care and Research, Hamad Medical Corporation","place":["Doha, Qatar"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fatihelmgib","family":"Mohamed","sequence":"additional","affiliation":[{"name":"Department of Public and Environmental Health, Faculty of Medicine, Gezira University","place":["Wad Madani, Sudan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marwa","family":"Osman","sequence":"additional","affiliation":[{"name":"Faculty of Medicine, Shendi University","place":["Shendi, Sudan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mujahid O.","family":"Abdelraof","sequence":"additional","affiliation":[{"name":"Department of Public and Environmental Health, Faculty of Medicine, Gezira University","place":["Wad Madani, Sudan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mona","family":"Al Rasheed","sequence":"additional","affiliation":[{"name":"Clinical Hematology Department, Adan Hospital","place":["Al Ahmadi, Kuwait"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hind","family":"Salama","sequence":"additional","affiliation":[{"name":"Adult Hematology Department, King Abdulaziz Medical City","place":["Riyadh, Saudi Arabia"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shehab F.","family":"Mohamed","sequence":"additional","affiliation":[{"name":"Department of Hematology, National Center for Cancer Care and Research, Hamad Medical Corporation","place":["Doha, Qatar"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohamed A.","family":"Yassin","sequence":"additional","affiliation":[{"name":"Department of Hematology, National Center for Cancer Care and Research, Hamad Medical Corporation","place":["Doha, Qatar"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,4,10]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1186\/s13256-023-03808-1","article-title":"Successful use of emapalumab in refractory hemophagocytic lymphohistiocytosis in a child with ch\u00e9diak\u2013higashi syndrome: a case report","volume":"17","author":"AlAhmari","year":"2023","journal-title":"J. Med. Case Rep."},{"key":"B2","doi-asserted-by":"publisher","first-page":"857","DOI":"10.1136\/ard-2022-223739","article-title":"Efficacy and safety of emapalumab in macrophage activation syndrome","volume":"82","author":"Benedetti","year":"2023","journal-title":"Ann. Rheumatic Dis."},{"key":"B3","doi-asserted-by":"publisher","first-page":"263","DOI":"10.1016\/j.cytogfr.2014.10.001","article-title":"Hemophagocytic lymphohistiocytosis (HLH): a heterogeneous spectrum of cytokine-driven immune disorders","volume":"26","author":"Brisse","year":"2015","journal-title":"Cytokine Growth Factor Rev."},{"key":"B4","doi-asserted-by":"publisher","first-page":"443","DOI":"10.1111\/pde.14877","article-title":"A case of severe mosquito bite allergy complicated by fatal hemophagocytic lymphohistiocytosis","volume":"39","author":"Dupuy","year":"2022","journal-title":"Pediatr. Dermatol."},{"key":"B5","doi-asserted-by":"publisher","first-page":"1555415","DOI":"10.3389\/fimmu.2025.1555415","article-title":"Macrophage activation syndrome successfully treated with eculizumab and emapalumab: a case report","volume":"16","author":"Faggioli","year":"2025","journal-title":"Front. Immunol."},{"key":"B6","doi-asserted-by":"publisher","first-page":"887","DOI":"10.21037\/atm-20-3127","article-title":"Successful treatment of secondary macrophage activation syndrome with emapalumab in a patient with newly diagnosed adult-onset still\u2019s disease: case report and review of the literature","volume":"8","author":"Gabr","year":"2020","journal-title":"Ann. Transl. Med."},{"key":"B7","doi-asserted-by":"publisher","first-page":"927","DOI":"10.1007\/s00467-022-05692-1","article-title":"Use of extracorporeal immunomodulation in a toddler with hemophagocytic lymphohistiocytosis and multisystem organ failure","volume":"38","author":"Goldstein","year":"2023","journal-title":"Pediatr. Nephrol."},{"key":"B8","doi-asserted-by":"publisher","first-page":"104","DOI":"10.1186\/s12969-022-00764-w","article-title":"Hemophagocytic lymphohistocytosis in trisomy 21: successful treatment with interferon inhibition","volume":"20","author":"Guild","year":"2022","journal-title":"Pediatr. Rheumatol."},{"key":"B9","doi-asserted-by":"publisher","first-page":"1340360","DOI":"10.3389\/fped.2023.1340360","article-title":"Case report: successful avoidance of etoposide for primary hemophagocytic lymphohistiocytosis-induced multiple organ dysfunction syndrome using emapalumab","volume":"11","author":"Hahn","year":"2024","journal-title":"Front. Pediatr."},{"key":"B10","doi-asserted-by":"publisher","first-page":"584","DOI":"10.1056\/NEJMra2314005","article-title":"Hemophagocytic in lymphohistiocytosis","volume":"392","author":"Henter","year":"2025","journal-title":"N. Engl. J. Med."},{"key":"B11","doi-asserted-by":"publisher","first-page":"438.e1","DOI":"10.1016\/j.jtct.2023.03.006","article-title":"Immune effector cell-associated hemophagocytic lymphohistiocytosis-like syndrome","volume":"29","author":"Hines","year":"2023","journal-title":"Transpl. Cell Ther."},{"key":"B12","doi-asserted-by":"publisher","first-page":"663","DOI":"10.21037\/tp-24-72","article-title":"Case report: emapalumab treatment for a pediatric epstein-barr virus-associated hemophagocytic lymphohistiocytosis (EBV-HLH) patient with cytokine storm enabling allogeneic hematopoietic cell transplantation","volume":"13","author":"Jia","year":"2024","journal-title":"Transl. Pediatr."},{"key":"B13","doi-asserted-by":"publisher","first-page":"2998","DOI":"10.3324\/haematol.2023.284179","article-title":"Emapalumab as salvage therapy for adults with malignancy-associated hemophagocytic lymphohistiocytosis","volume":"109","author":"Johnson","year":"2024","journal-title":"Haematol"},{"key":"B14","doi-asserted-by":"publisher","first-page":"28","DOI":"10.3390\/hematolrep17030028","article-title":"Management of refractory malignancy-associated hemophagocytic lymphohistiocytosis in adolescent patients: a case series of novel therapeutics and treatment challenges","volume":"17","author":"Krishnareddigari","year":"2025","journal-title":"Hematol. Rep."},{"key":"B15","doi-asserted-by":"publisher","first-page":"2465","DOI":"10.1182\/blood.2018894618","article-title":"Recommendations for the management of hemophagocytic lymphohistiocytosis in adults","volume":"133","author":"La Ros\u00e9e","year":"2019","journal-title":"Blood"},{"key":"B16","doi-asserted-by":"publisher","first-page":"2778","DOI":"10.1084\/jem.20190147","article-title":"A novel disorder involving dyshematopoiesis, inflammation, and HLH due to aberrant CDC42 function","volume":"216","author":"Lam","year":"2019","journal-title":"J. Exp. Med."},{"key":"B17","doi-asserted-by":"publisher","first-page":"1811","DOI":"10.1056\/NEJMoa1911326","article-title":"Emapalumab in children with primary hemophagocytic lymphohistiocytosis","volume":"382","author":"Locatelli","year":"2020","journal-title":"N. Engl. J. Med."},{"key":"B18","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1182\/bloodadvances.2018025858","article-title":"Treatment of refractory hemophagocytic lymphohistiocytosis with emapalumab despite severe concurrent infections","volume":"3","author":"Lounder","year":"2019","journal-title":"Blood Adv."},{"key":"B19","doi-asserted-by":"publisher","first-page":"e002611","DOI":"10.1136\/rmdopen-2022-002611","article-title":"Complications of complications: diagnosis and treatment of recurrent macrophage activation syndrome in a patient with well-controlled systemic juvenile idiopathic arthritis","volume":"9","author":"Macaraeg","year":"2023","journal-title":"RMD Open"},{"key":"B20","doi-asserted-by":"publisher","first-page":"382","DOI":"10.3390\/genes16040382","article-title":"Systemic EBV+ T-Cell lymphoma of childhood with hemophagocytic lymphohistiocytosis in a patient with a highly complex karyotype","volume":"16","author":"Maher","year":"2025","journal-title":"Genes"},{"key":"B21","doi-asserted-by":"publisher","first-page":"1563736","DOI":"10.3389\/fimmu.2025.1563736","article-title":"Case report: successful use of emapalumab in adult B-cell acute lymphoblastic leukemia experiencing severe neurotoxicity and hemophagocytic lymphohistiocytosis-like features after CAR-T cell therapy","volume":"16","author":"Manghisi","year":"2025","journal-title":"Front. Immunol."},{"key":"B22","doi-asserted-by":"publisher","first-page":"681055","DOI":"10.3389\/fped.2021.681055","article-title":"Case report: rapid recognition and immune modulation of secondary HLH due to disseminated HSV infection","volume":"9","author":"McKeone","year":"2021","journal-title":"Front. Pediatr."},{"key":"B23","doi-asserted-by":"publisher","first-page":"90","DOI":"10.1158\/2643-3230.BCD-21-0203","article-title":"Potential role of IFN\u03b3 inhibition in refractory cytokine release syndrome associated with CAR T-cell therapy","volume":"3","author":"McNerney","year":"2022","journal-title":"Blood Cancer Discov."},{"key":"B24","doi-asserted-by":"publisher","first-page":"2314","DOI":"10.3324\/haematol.2019.216101","article-title":"Role of interferon-\u03b3 in immune-mediated graft failure after allogeneic hematopoietic stem cell transplantation","volume":"104","author":"Merli","year":"2019","journal-title":"Haematologica"},{"key":"B25","doi-asserted-by":"publisher","first-page":"406","DOI":"10.1038\/s41409-024-02487-w","article-title":"Emapalumab for the treatment of immune-mediated graft failure after HSCT","volume":"60","author":"Merli","year":"2025","journal-title":"Bone Marrow Transpl."},{"key":"B26","doi-asserted-by":"publisher","first-page":"507","DOI":"10.5858\/arpa.2020-0802-RA","article-title":"Hemophagocytic lymphohistiocytosis","volume":"146","author":"Ponnatt","year":"2022","journal-title":"Arch. Pathol. Lab. Med."},{"key":"B27","doi-asserted-by":"publisher","first-page":"533","DOI":"10.1182\/bloodadvances.2022008256","article-title":"Interferon-\u03b3 blockade in CAR T-cell therapy\u2013associated macrophage activation syndrome\/hemophagocytic lymphohistiocytosis","volume":"7","author":"Rainone","year":"2023","journal-title":"Blood Adv."},{"key":"B28","doi-asserted-by":"publisher","first-page":"1543622","DOI":"10.3389\/fonc.2025.1543622","article-title":"Emapalumab for severe cytokine release syndrome in solid tumor CAR-T: a case report","volume":"15","author":"Ruemmele","year":"2025","journal-title":"Front. Oncol."},{"key":"B29","doi-asserted-by":"publisher","first-page":"3439","DOI":"10.3324\/haematol.2023.284784","article-title":"Treatment strategies for progressive immune effector cell-associated hemophagocytic lymphohistiocytosis-like syndrome: case series","volume":"109","author":"Scala","year":"2024","journal-title":"Haematologica"},{"key":"B30","doi-asserted-by":"publisher","first-page":"5603","DOI":"10.1182\/bloodadvances.2023010712","article-title":"Emapalumab for the treatment of refractory cytokine release syndrome in pediatric patients","volume":"7","author":"Schuelke","year":"2023","journal-title":"Blood Adv."},{"key":"B31","doi-asserted-by":"publisher","first-page":"1336554","DOI":"10.3389\/fped.2023.1336554","article-title":"Case report: refractory macrophage activation syndrome requiring high-dose anakinra, emapalumab, and etoposide therapy in early-onset systemic juvenile idiopathic arthritis associated with adenoviremia","volume":"11","author":"Slaney","year":"2024","journal-title":"Front. Pediatr."},{"key":"B32","doi-asserted-by":"publisher","first-page":"70","DOI":"10.1038\/s41408-024-01056-0","article-title":"Combined emapalumab and ruxolitinib in patients with haemophagocytic lymphohistiocytosis","volume":"14","author":"Song","year":"2024","journal-title":"Blood Cancer J."},{"key":"B33","doi-asserted-by":"publisher","first-page":"581475","DOI":"10.3389\/fimmu.2020.581475","article-title":"Case report: secondary hemophagocytic lymphohistiocytosis with disseminated infection in chronic granulomatous disease\u2014A serious cause of mortality","volume":"11","author":"Squire","year":"2020","journal-title":"Front. Immunol."},{"key":"B34","doi-asserted-by":"publisher","first-page":"e29026","DOI":"10.1002\/pbc.29026","article-title":"Combined use of emapalumab and ruxolitinib in a patient with refractory hemophagocytic lymphohistiocytosis was safe and effective","volume":"68","author":"Triebwasser","year":"2021","journal-title":"Pediatr. Blood and Cancer"},{"key":"B35","doi-asserted-by":"publisher","first-page":"641","DOI":"10.3324\/haematol.2020.255620","article-title":"Emapalumab treatment in an ADA-SCID patient with refractory hemophagocytic lymphohistiocytosis-related graft failure and disseminated bacillus calmette-gu\u00e9rin infection","volume":"106","author":"Tucci","year":"2021","journal-title":"Haematologica"},{"key":"B36","doi-asserted-by":"publisher","first-page":"1783","DOI":"10.1182\/blood.2019002289","article-title":"Emapalumab for the treatment of relapsed\/refractory hemophagocytic lymphohistiocytosis","volume":"134","author":"Vallurupalli","year":"2019","journal-title":"Blood"},{"key":"B37","doi-asserted-by":"publisher","first-page":"e39880","DOI":"10.1097\/MD.0000000000039880","article-title":"Emapalumab as a therapeutic intervention for epstein\u2013barr virus-associated hemophagocytic lymphohistiocytosis: a case series","volume":"103","author":"Wang","year":"2024","journal-title":"Medicine"},{"key":"B38","doi-asserted-by":"publisher","first-page":"e247022","DOI":"10.1136\/bcr-2021-247022","article-title":"Haemophagocytic lymphohistiocytosis following COVID-19 mRNA vaccination","volume":"15","author":"Wu","year":"2022","journal-title":"BMJ Case Rep."},{"key":"B39","doi-asserted-by":"publisher","first-page":"106","DOI":"10.1186\/s13045-024-01621-x","article-title":"Hemophagocytic lymphohistiocytosis: current treatment advances, emerging targeted therapy and underlying mechanisms","volume":"17","author":"Wu","year":"2024","journal-title":"J. Hematol. Oncol."},{"key":"B40","doi-asserted-by":"publisher","first-page":"1705","DOI":"10.1007\/s10067-025-07352-9","article-title":"Salvage treatment of AOSD-Associated macrophage activation syndrome with bariticinib following conventional immunosuppressive therapy","volume":"44","author":"Xu","year":"2025","journal-title":"Clin. Rheumatol."},{"key":"B41","doi-asserted-by":"publisher","first-page":"102162","DOI":"10.1016\/j.trim.2024.102162","article-title":"Low-dose emapalumab combined with chemotherapy for adult patients with epstein\u2013barr virus-associated hemophagocytic lymphohistiocytosis","volume":"88","author":"Zhu","year":"2025","journal-title":"Transpl. Immunol."}],"container-title":["Frontiers in Pharmacology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2026.1749084\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,10]],"date-time":"2026-04-10T06:06:41Z","timestamp":1775801201000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2026.1749084\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4,10]]},"references-count":41,"alternative-id":["10.3389\/fphar.2026.1749084"],"URL":"https:\/\/doi.org\/10.3389\/fphar.2026.1749084","relation":{},"ISSN":["1663-9812"],"issn-type":[{"value":"1663-9812","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,4,10]]},"article-number":"1749084"}}